Boston Scientific Corporation
BSX · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5,065 | $5,061 | $4,663 | $4,561 |
| % Growth | 0.1% | 8.5% | 2.2% | – |
| Cost of Goods Sold | $1,523 | $1,637 | $1,713 | $1,890 |
| Gross Profit | $3,542 | $3,424 | $2,950 | $2,671 |
| % Margin | 69.9% | 67.7% | 63.3% | 58.6% |
| R&D Expenses | $514 | $526 | $443 | $460 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,741 | $1,716 | $1,597 | $1,612 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $237 | $363 | $14 | $10 |
| Operating Expenses | $2,492 | $2,605 | $2,054 | $2,082 |
| Operating Income | $1,050 | $819 | $896 | $589 |
| % Margin | 20.7% | 16.2% | 19.2% | 12.9% |
| Other Income/Exp. Net | -$111 | $122 | -$91 | -$4 |
| Pre-Tax Income | $939 | $941 | $805 | $585 |
| Tax Expense | $183 | $146 | $133 | $23 |
| Net Income | $755 | $793 | $674 | $566 |
| % Margin | 14.9% | 15.7% | 14.5% | 12.4% |
| EPS | 0.51 | 0.54 | 0.456 | 0.384 |
| % Growth | -5.6% | 18.3% | 18.9% | – |
| EPS Diluted | 0.5 | 0.53 | 0.451 | 0.38 |
| Weighted Avg Shares Out | 1,482 | 1,479 | 1,477 | 1,474 |
| Weighted Avg Shares Out Dil | 1,496 | 1,493 | 1,493 | 1,490 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $22 |
| Interest Expense | $87 | $90 | $87 | $139 |
| Depreciation & Amortization | $0 | $336 | $325 | $348 |
| EBITDA | $1,026 | $1,367 | $1,217 | $1,071 |
| % Margin | 20.3% | 27% | 26.1% | 23.5% |